Welcome to the e-CCO Library!

Generating complex data to unravel IBD
Year: 2021
Source: 7th Y-ECCO Basic Science Workshop
Authors: Stefan Wolfgang Schreiber
Created: Friday, 1 October 2021, 12:41 PM
Genetics
Year: 2017
Source: 15th IBD Intensive Advanced Course
Authors: Parkes M.
Last Modified: Friday, 16 April 2021, 2:19 PM by ECCO Administrator
Autophagy, Genetics, Immunology, Lymphocyte, T Cell
Files: 1
Genetics and function in IBD: The missing link?
Year: 2017
Source: ECCO'17 Barcelona
Authors: Zeissig S.
Last Modified: Wednesday, 15 March 2017, 2:15 PM by ECCO Administrator
Immunology
Files: 1
Get your patient fit for surgery
Year: 2018
Source: ECCO'18 Vienna
Authors: Kotze Paulo
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
Getting Published!
Year: 2022
Source: 8th Y-ECCO Basic Science Workshop
Authors: Laurence Egan
Created: Tuesday, 24 May 2022, 8:13 PM
Summary content

In this lecture, I will discuss the essential ingredients to doing excellent research which the prerequisite to getting your work published in the best journals, such as the Journal of Crohn's and Colitis. I will also give an overview of how to pick the right journal and review the processes that editors use to select what to publish.

Educational objectives
1. To learn the essential ingredients for good research
2. To understand how to target your work to the best journal
3. To understand how your paper is evaluated by editors using the peer review process

Gi dysplasia and reactive atypia: can we agree and does p53 help?
Year: 2020
Source: 5th H-ECCO IBD Masterclass
Authors: Gert De Hertogh
Created: Tuesday, 23 June 2020, 5:40 PM
GRADE-ing Guidelines: ECCO CD Treatment (Tandem talk)
Year: 2020
Source: ECCO'20 Vienna
Authors: Michel Adamina, Joana Tinoco da Silva Torres
Created: Tuesday, 23 June 2020, 5:40 PM
Growth and bone health in patients with IBD
Year: 2019
Source: 4th D-ECCO Workshop
Authors: David Wilson
Created: Wednesday, 5 June 2019, 9:01 PM
Handling biologics around pregnancy
Year: 2018
Source: Transatlantic Talking Heads
Authors: Christina Ha, Uma Mahadevan, Iris Dotan
Created: Friday, 28 February 2020, 3:06 PM by Dauren Ramankulov
Last Modified: Monday, 17 August 2020, 10:36 AM by Dauren Ramankulov
Head to head trials
Year: 2021
Source: ECCO'21 Virtual
Authors: Subrata Ghosh
Created: Friday, 1 October 2021, 12:41 PM
Summary content

1. To understand the objectives and necessity of head to head trials of new targeted therapies against active comparators in IBD

2. To understand the types of head to head trials in IBD

3. To follow the details of completed head to head trials in IBD and their conclusions

4. To interpret recently completed head to head trials in IBD 

Hedgehog signalling controls Th17 differentiation to drive intestinal inflammation and is a druggable target for the treatment of IBD
Year: 2022
Source: ECCO'22 Virtual
Authors: Joachim Hanna
Created: Tuesday, 24 May 2022, 8:13 PM
Background

T helper 17 (Th17) cells play an important role in barrier protection in the gastrointestinal tract but are also key pathological drivers of Inflammatory Bowel Disease (IBD). Although a number of transcription factors governing Th17 differentiation have been identified, the intracellular signalling pathways regulating Th17 differentiation are poorly understood. Hedgehog (Hh) signalling controls cell-fate choices in numerous tissue compartments and is targetable by highly selective, clinically-approved small molecule inhibitors. However the role of Hh signalling in Th17 differentiation and effector function is unstudied.

Methods

We generated two conditional knockout mouse models targeting Hh signalling components Smo and Ihh to study Th17 differentiation in vitro by flow cytometry and gene expression analysis. For in vivo studies, T cell adoptive transfer colitis was performed using donor Ihh knockout T cells or heterozygote controls. Histological analysis, mouse weight, colon length/weight measurements, and flow cytometric analysis was performed. We supplement this with the use of two small-molecule Smo antagonists for in vitro and in vivo studies of Th17 function. To underscore the translational relevance of our findings, we conducted bioinformatic analyses of published gene expression datasets of human rectal biopsies from two large independent cohorts of Ulcerative Colitis patients and healthy controls.

Results

We find that intracellular Hh signalling, independently of extracellular Hh ligands, selectively drives differentiation and effector function of Th17 cells but not of other T helper cell lineages. We demonstrate in vivo that inhibition of the Hh pathway with either the clinically-approved small molecule inhibitor vismodegib or genetic ablation of Ihh in CD4T cells results in a significant decrease in histological and clinical readouts of disease severity as well as a significant reduction in IL-17a+ Th17 cells. Our bioinformatic analyses show that Hh component expression levels are upregulated in human Ulcerative Colitis patient samples and are closely correlated with expression of Th17 markers. Mechanistically we show that the T-cell-intrinsic Indian Hedgehog (Ihh) ligand signals via the signal transducer Smoothened to activate both canonical and non-canonical Hh pathways, through the Gli3 transcription factor and AMPK phosphorylation, respectively.

Conclusion

We uncover Hh signalling as a novel pathway controlling Th17 differentiation and pathogenicity in IBD with Gli3 acting as a newly-identified crucial regulatory transcription factor. Our work paves the way for the use of Hh inhibitors for the treatment of IBD.

Highlights of ECCO'20
Year: 2020
Source: Talking Heads
Authors: Silvio Danese, Laurent Peyrin-Biroulet
Created: Monday, 27 July 2020, 11:56 AM by Dauren Ramankulov
Last Modified: Wednesday, 2 June 2021, 12:26 PM by ECCO Administrator
Histologic disease activity correlates with endoscopic severity in patients with moderate to severe Crohn’s Disease
Year: 2022
Source: ECCO'22 Virtual
Authors: Walter Reinisch
Created: Tuesday, 24 May 2022, 8:13 PM
Background

The role of histopathology evaluation in Crohn’s disease (CD) is not precisely defined. Due to the heterogeneity of phenotypes, the discontinuity of distribution, and the transmural nature of inflammation, the interpretation of histologic outcomes is complex. To analyze how histology relates to established outcomes in CD, we examined association between histologic and endoscopic disease activity measured by frequently used scores (simple endoscopic score for Crohn’s disease [SES-CD], Robarts histopathology index [RHI], global histological activity score [GHAS]) and the association between histologic or endoscopic severity with inflammatory biomarkers in a cohort of patients with moderate-to-severe CD.

Methods

Patients (N=191) who were enrolled in a phase 2 randomized clinical trial (NCT02891226) in patients with moderate-to-severe CD were assessed at baseline (BL) for endoscopic disease location and severity as measured by SES-CD. Biopsies were obtained during BL endoscopy from the edge of the ulcers and the most inflamed mucosa in terminal ileum and 4 colonic segments (ascending, transverse, descending, rectum; N=10/patient, 2 per location with the more severe score used), and scored by central readers blind to study treatment, timepoint, and response status using RHI and both modified and active GHAS (mGHAS: Q1, 3, 4, 5, 6; aGHAS: Q1, 4, 5, 6; see Fig. 1). Inflammatory biomarkers included fCLP and CRP; log-transformed values are used. Linear correlations between measures were determined using Pearson correlation coefficients (PCC) as exploratory analyses. Nominal p values are presented.

Results

SES-CD correlated well with all 3 histologic measures examined (Fig. 1). While both fCLP and CRP correlated more closely with endoscopy than with histologic measures, fCLP had higher correlation with each histologic measure than CRP (Fig. 2). 64% of patients had the same disease location at BL when measured by endoscopy or histology. Patients with endoscopic colonic disease displayed histologic ileal involvement in up to 20% of cases, while 13% of patients with endoscopic ileal disease demonstrated histologic colonic involvement (Table 1).

Conclusion

Although histologic disease activity in CD, as determined by 3 different measures, correlates well with endoscopic assessment of disease, histologic involvement provides complementary information on disease distribution and extension. Further analyses are required to understand the additive role of mucosal histology in CD.





Histologic markers of chronicity of IBD
Year: 2022
Source: 7th H-ECCO IBD Masterclass
Authors: Pamela Baldin
Created: Tuesday, 24 May 2022, 8:13 PM
Summary content

Differential  diagnosis of IBD and chronic colitis could be challenging. In this presentation the histological features of chronicity in IBD will be resumed  and differential diagnosis pointed out.

Educational objectives:
- understand the main features of chronicity of IBD
- compare these features with the main differential diagnosis.

Histopathology Scores
Year: 2019
Source: Talking Heads
Authors: Gert de Hertogh, Francesca Rosini
Created: Friday, 28 February 2020, 3:59 PM by Dauren Ramankulov
Host and microbial metabolites as therapeutic targets in IBD
Year: 2022
Source: 10th SciCom Workshop
Authors: Konrad Aden
Created: Tuesday, 24 May 2022, 8:13 PM
Summary content

. to understand the role of metabolism in IBD
- to identifiy key metabolic principles (SCFA, Bile Acid, Tryptophan)  that have shown to be relevant in the pahtophysiology of IBD

Hot topics in IBD
Year: 2020
Source: 5th H-ECCO IBD Masterclass
Authors: Magali Svrcek
Created: Tuesday, 23 June 2020, 5:40 PM
Hot topics in IBD
Year: 2021
Source: 6th H-ECCO IBD Masterclass
Authors: Gert De Hertogh
Created: Friday, 1 October 2021, 12:41 PM
Summary content

Hot topics list (2020-2021)
1.Disease mechanisms
2.(Differential) diagnoses
3.COVID-19
4.Endoscopy scoring
5.Histology
6.Clinical trials involving histology
7.IBD-associated neoplasia

Hot topics in IBD
Year: 2022
Source: 7th H-ECCO IBD Masterclass
Authors: Gert De Hertogh
Created: Tuesday, 24 May 2022, 8:13 PM
Summary content

Educational objectives:
Give an overview of recently published work on IBD / Crohn's disease / ulcerative colitis

Summary
Possible subjects will include:
1) Very early-onset IBD
2) Granulomatous gastritis
3) Appendiceal inflammation in Crohn's disease and in ulcerative colitis
4) An important differential diagnosis of Crohn's disease
5) Precursor lesions of IBD-associated neoplasia and features of Crohn's and colitis-associated bowel cancer
6) Something that may come as a surprise

How do we measure quality in guidelines?
Year: 2021
Source: 2nd Guideline Methodology and GRADE Workshop
Authors: Joana Tinoco da Silva Torres
Created: Friday, 1 October 2021, 12:41 PM
Summary content

1. To address the importance of developing high-quality guidelines
2. To address some of the issues behind guideline quality variability
3. To discuss the different domains that dictate standards of quality in guidelines